NCT06874231Recruiting
Brain Connectivity Marker for Alzheimer's Disease
Clinical Application of a Brain Connectivity Marker for Early Detection of Alzheimer's Disease
Source: ClinicalTrials.gov · Last updated 17 Mar 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The main purpose of this project is to establish whether changes in brain connectivity can be used to predict the development of Alzheimer's disease (AD).
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 120 (estimated)
- First submitted
- 4 Apr 2023
- Start date
- 1 Apr 2023
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- Karolinska Institutet
- Diseases
- Alzheimer disease
- NCT number
- NCT06874231
What you commit to
- Study type: Observational
- Planned participants: 120
- From 1 Apr 2023 to the primary completion date, 31 Jul 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Alcohol or drug abuse.
- Refuse to cerebrospinal fluid testing and/or blood sampling, neuropsychological testing, brain imaging, electroencephalogram or magnetoencephalogram.
- In addition, participants who have claustrophobia or some form of metal implant in their body that may interfere with the brain imaging scan will be excluded from the study.
Other illness
- Unstable somatic disease or organ failure.
Who the study is looking for
- Inclusion criteria for subjects with subjective cognitive complaints:
- MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 26 and 30.
- Absence of cognitive impairment.
- Memory problems reported by the participant/family member.
- Do not fulfill criteria for mild cognitive impairment or dementia.
- Must speak and understand Swedish.
- Inclusion criteria for patients with mild cognitive impairment:
- MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 24 and 30.
- Impaired memory function.
- Do not fulfill criteria for dementia.
- Must speak and understand Swedish.
- Must have abnormal cerebrospinal fluid amyloid-β 42/40 ratio levels, which is a biomarker of Alzheimer's disease.
- Specific inclusion criteria for patients with Alzheimer's disease:
- MMSE (Mini-mental test) or MoCA (Montreal Cognitive Assessment) points between 18 and 28.
- Impaired memory function in addition to impaired executive abilities, language function, visuospatial ability and/or attention/psychomotor speed.
- Meet NINCDS-ADRDA and DSM-IV criteria for probable Alzheimer's disease.
- Must speak and understand Swedish.
- Must have abnormal spinal fluid amyloid-β 42/40 ratio levels, which is a biomarker of Alzheimer's disease.
Age in the registry: 40 years to 85 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Karolinska University Hospital Coordinator of this site? Confirm its status | Stockholm | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.